Single-cell profiling of EZH2-mediated immune signaling perturbations in NSCLC

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Lung cancer remains a significant public health burden. One of the most personalized treatments uses a patient’s own tumor infiltrating lymphocytes (TILs), and TIL activity is also essential for immune checkpoint inhibitor (ICI) effectiveness. Responses to immunotherapies vary due to immune-suppressive tumor microenvironments (TMEs) and limited antigen presentation. In this study, we computationally examine cell-cell signaling and transcriptional activity using single-cell RNA sequencing of lung cancer treated by inhibiting methyltransferase EZH2. We show that EZH2 inhibition shifts the TME to immunogenic signaling patterns conducive to increased T cell response, including antigen presentation and homing. T cells also showed more stem-like phenotypes. Transcriptional activity was quieter with EZH2 inhibition but revealed better interferon response, altered myeloid and B cell differentiation, and apoptotic markers. Importantly, inferred EZH2 activity showed it could perform non-methyltransferase duties vital for T cell differentiation. These results indicate that EZH2 inhibition could improve immunotherapies for lung cancer patients.

Article activity feed